Innovative drugs refer to new drugs with independent intellectual property rights, which are safe, effective and internationally competitive, and are the core driving force of the pharmaceutical industry. What are the innovative medicine leading stocks brought by the following small series? Let's take a look at it together, hoping to bring some reference.

What are the leading stocks of innovative drugs?

1, Cisco: leading.

In the second quarter of 2022, Heiske Company mainly engaged in raw materials and patented technology, parenteral nutrition and anesthetic products. The revenue was 332 million yuan, 296.5438+0.8 billion yuan and 65.438+0.29 billion yuan, accounting for 26.58%, 23.3% and 654.38+0.34% respectively.

The financial report shows that in the third quarter of 2022, the company's operating income was 849 million yuan; The net profit attributable to listed shareholders is 33,229,654,38+0,000 yuan; The income from fully diluted net assets is1.17%; Gross profit margin is 66.33%, and earnings per share is 0.03 yuan.

2. Baekje Shenzhou: Leader

In the second quarter of 2022, Baekje Shenzhou Company mainly engaged in Brookings/Baiyueze, Baizean, technology licensing, R&D services and intellectual property licensing, with revenues of 65.438+0.565438+0.40 billion yuan, 65.438+0.2565438 billion yuan and 534 million yuan respectively, accounting for 3.54 billion yuan.

The financial report shows that in the third quarter of 2022, the company's operating income was 2.659 billion yuan; The net profit attributable to listed shareholders is-3.77 billion yuan; Earnings on fully diluted net assets-10.97%; Gross profit margin is 80.84%, and earnings per share is -2.8 1 yuan.

3. Xinlitai: Leader

In the second quarter of 2022, Xinlitai Company mainly engaged in preparations, raw materials and instruments, with revenues of 65.438+46.3 million yuan, 65.438+34 million yuan and 50.65438+50 million yuan respectively, accounting for 87.7 1% and 8.0 1.

The financial report shows that in the third quarter of 2022, the company's operating income was 880 million yuan; The net profit attributable to listed shareholders is 1.9 1 100 million yuan; Fully diluted net asset income of 2.47%; Gross profit margin is 72.68%, and earnings per share is 0. 18 yuan.

4, Hengrui Pharma: faucet

20021In the fourth quarter, Hengrui Pharma Company mainly engaged in anti-tumor, anesthesia and contrast agents. , the revenue was 65.438+03.072 billion yuan, 49 16 billion yuan and 3.27 billion yuan respectively, accounting for 50.46%, 654.38+08.98% and 654.38+02 respectively.

Hengrui Pharma released its financial report for the third quarter of 2022, achieving an operating income of 5710.70 billion yuan, a year-on-year increase of-17. 16%, and a net profit of154 million yuan, a year-on-year increase of-310.54%. Earnings per share is 0. 17 yuan.

What are the listed companies of innovative drug concept stocks?

1, Wuxi pharmatech (603259): The company is mainly engaged in pharmaceutical research and development services. 65438+Opening news on February 27th, the latest offer of WuXi PharmaTech was 78.940 yuan, up 1.58%, and its share price rose by 2.43% within three days. Since the beginning of this year, the growth rate has dropped by -37.83%, and the price-earnings ratio is 45. 1 1.

2. zhifei Bio (300 122): The company is engaged in research and development, production and sales of vaccines and biological products. On February 27th, 65438, the stock price of zhifei Bio rose by 2.48% in three days, the latest price was 87.580 yuan, and the turnover was165438+72 million yuan.

3. Tiger Medicine (300347): The company specializes in professional clinical research services. 65438+opening news on February 27th, Tiger Pharmaceutical's latest offer was 102.900 yuan, and its share price rose by 5.23% in three days, with a price-earnings ratio of 3 1.09.

4. Huadong Pharmaceutical (000963): The company is engaged in pharmaceutical industrial production and pharmaceutical commercial circulation. On February 27th, 65438, the share price of Huadong Pharmaceutical rose by 6.74% in seven days. At the close, the stock reported 46.620 yuan, up 6.76%, with a total market value of 8 177 1 100 million yuan.

5. Kanglong Chenghua (300759): The company is engaged in research and development services for small molecule drugs. On February 27th, 65438, the share price of Kanglong Huacheng rose by 9.45% in five days, and the latest price was 64.3 10 yuan, with a turnover of1057200 lots, with a total market value of 76.598 billion yuan.

6. Changchun High-tech (00066 1): The company's business includes research and development, production and sales of biopharmaceuticals and Chinese patent medicines. 65438+opening news on February 27th, Changchun Gaoxin's latest offer 17 1.900 yuan, the share price rose by 0.89% in three days, and the price-earnings ratio 18.52.

7. Shanghai Pharmaceutical (60 1607): The company's main business is pharmaceutical R&D and manufacturing, distribution and retail. 65438+ Opening News On February 27th, the latest news of Shanghai Pharmaceutical 18. 150 yuan dropped by 3.82%. The turnover was 2923 1.8 million lots, with a total market value of 67.09 billion yuan.

8. watson biological (300 142): The company is engaged in research and development, production and sales of biotechnology drugs such as vaccines. 65438+opening news on February 27th, watson biological's latest offer was 39.020 yuan, and its share price fell by 2.46% in three days, with a price-earnings ratio of 143.09.

9. Yiling Pharmaceutical (002603): The company is mainly engaged in research and development, production and sales of drugs. 65438+The latest news on February 27th, Yiling Pharmaceutical has increased by 37.42% this year. As of 15, the stock has fallen by 7.69% to 32.520 yuan.

What are the leading stocks of pharmaceutical listed companies?

The leading shares of listed pharmaceutical companies are Tencent Holdings Limited, Yao Ming Bio and China Bio-Pharmaceutical.

1. Tencent Holdings Limited (00700. HK): Tencent Medical Health, a pharmaceutical subsidiary of Tencent, is one of the leading Internet medical platforms in China and one of the leading enterprises in the pharmaceutical industry.

2. Yao Ming Biology (02269. HK): A biopharmaceutical company specializing in innovative drug research and development, and one of the largest drug research and development outsourcing service providers in China.

3. Yao Ming Biology (02269. HK): A biopharmaceutical company specializing in innovative drug research and development, and one of the largest drug research and development outsourcing service providers in China.

The most potential biomedical leading stock

The potential biomedical leading stocks are as follows:

1. Hengrui Pharma, the first innovative drug in China (600276). The main product lines are anti-tumor, anesthesia, contrast agent and so on. The company's return on net assets has remained above 23% for many years, and its net profit has maintained a growth rate of above 20% for many years. The company has strong R&D strength, excellent management team and strong sales ability.

2. Aier Ophthalmology (3000 15), the first unit of domestic ophthalmology chain hospitals. Mainly to provide patients with various ophthalmic diseases diagnosis and treatment, medical optometry and other ophthalmic medical services. The company's return on net assets has remained around 20% for many years, and its net profit has maintained a growth rate of more than 30% for many years.

3. The first domestic medical device, Mindray Medical (300760). The main product lines are life and information support, in vitro diagnosis, medical imaging and so on. The company's return on net assets has remained above 25% for many years, and its net profit has maintained a growth rate of above 25% for many years.

Top ten leading stocks in biomedicine

1. Hengrui Pharma, the first innovative drug in China (600276). The main product lines are anti-tumor, anesthesia, contrast agent and so on. Company's network

The return on assets has remained above 23% for many years, and the growth rate of net profit has remained above 20% for many years. The company's research and development strength is very strong.

Excellent management team and strong sales ability.

2. Aier Ophthalmology (3000 15), the first unit of domestic ophthalmology chain hospitals. It mainly provides patients with the diagnosis and treatment of various ophthalmic diseases.

And ophthalmic medical services such as medical optometry and glasses. The company's return on net assets has remained at around 20% for many years, and its net profit has remained at 30% for many years.

The above speed increases. The company's business model is excellent, and its business ability and brand reputation continue to improve.

3. The first domestic medical device, Mindray Medical (300760). The main product lines are life and information support, in vitro diagnosis and medicine.

Images, etc. The company's return on net assets has remained above 25% for many years, and its net profit has maintained a growth rate of above 25% for many years. Company work

In order to complete the global layout of medical devices, the high-end and platformization have been steadily promoted, with a very stable position and huge long-term space.

Changchun Hi-Tech (00066 1) is the first biopharmaceutical company in China. The main product lines are growth hormone and syncytial virus vaccine. company

The return on net assets has remained above 16% for many years, and the growth rate of net profit has remained above 30% for many years. As a biomedical company in China.

Drug leader, performance exceeded expectations.

Five, domestic pharmaceutical research and development services, the first drug, Wuxi PharmaTech (603259). The main business is the discovery, research and development and production of small molecular chemicals.

Produce all-round and integrated platform services. The company's return on net assets has remained above 20% for many years and its net profit has remained at 25% for many years.

World growth rate. The company is the world's leading pharmaceutical R&D service platform, with broad market space and rapid growth in performance.

6. Tiger Medicine (300347), the leading clinical contract research institution (CRO) in China. The main business is to provide research and development for pharmaceutical products.

Provide technical services and data management and other clinical research services for phase I to IV clinical trials. The company's return on net assets has increased to 17% in recent two years.

Around, the net profit has maintained a growth rate of more than 56% for many years.

Seven, my martial arts (300357), the first desensitization diagnosis and treatment in China. The company's Dermatophagoides farinae drops keep growing at a high speed, and the heavy product is yellow flowers.

Artemisia pollen sublingual drops are verified in the market and are expected to be approved for marketing in 2020. The company's return on net assets has remained at 265,438+0% for many years.

In fact, net profit has maintained a growth rate of more than 25% for many years. As the only leading hypoglossal desensitization enterprise in China, the company has a competitive pattern.

Excellent, the market share exceeds 80%, and the company has great long-term growth potential.

Eight, the first domestic dental chain Tongce Medical (600763). The company passed the "hospital replicable+doctor replicable+team replicable"

Mode, expand the layout of dental chain hospitals. The company's return on net assets has remained at around 23% and its net profit has remained at around 50% for many years.

The right wing is getting faster and faster. China has a vast dental market, and the company is expected to achieve rapid growth under the two major trends of aging population and consumption upgrading.

Rapid development.

Nine, Antu Bio (603658), the leading stock of domestic IVD. The company is mainly engaged in the research and development and production of in vitro diagnostic reagents and their supporting instruments.

And sales. The company's return on net assets has remained around 30% for many years, and its net profit has maintained a growth rate of more than 25% for many years. Chemical hair

The glasses industry will enter the era of differentiation. With 70% biological raw material assets, mainstream projects, assembly lines and other advantages, the company is expected to continue to replace.

Foreign investment and other domestic products maintained sustained growth.

X. Hualan Bio (002007) is the leading stock of domestic blood products. The company's main product lines are blood products and vaccine products. corporate

The return on net assets has remained at around 19% for many years, and the net profit has maintained a growth rate of around 30% for many years. With the slowdown of domestic blood products industry

With the slow recovery and the continuous increase of influenza vaccine, the company's performance is expected to further improve.